EUROAPI SA(EAPI)
HQ FR22% share
European API manufacturer spun off from Sanofi 2022; complex API synthesis including prostaglandin analogues (latanoprost, travoprost) at Frankfurt site; ~20–25% branded prostaglandin API supply.
pharmaceutical · input
Prostaglandin Analogue APIs (latanoprost, travoprost, bimatoprost)
Glaucoma first-line treatment APIs. Extremely complex chiral synthesis — reference price ~$1.26M/kg for latanoprost. Very few qualified API manufacturers globally. Gland Pharma (India, Fosun-owned) received FDA ANDA approval for generic latanoprost Dec 2024.
4
Source countries
3
Companies
1
Goods affected
0
Claims on record
What depends on it
Goods that need this input
1 essential American goods rely on prostaglandin analogue apis (latanoprost, travoprost, bimatoprost) somewhere upstream in their supply chain.
Where it comes from
Source countries
Share of global supply, by country.
| Country | Share of supply |
|---|---|
| FRFrance | 22% |
| USUnited States | 20% |
| TWTaiwan | 18% |
| INIndia | 12% |
Who makes it
Supplier companies
3 companies produce prostaglandin analogue apis (latanoprost, travoprost, bimatoprost).
Chirogate International Inc.
HQ TW18% share
Taiwanese specialty pharmaceutical API company (HQ Taipei; listed on Taiwan Stock Exchange); specializes in chiral synthesis of complex pharmaceutical intermediates and APIs including prostaglandin analogues (latanoprost, bimatoprost, travoprost) for ophthalmic glaucoma treatment. Chirogate's prostaglandin API capability is one of a very small number of commercial-scale chiral prostaglandin synthesis operations globally. Prostaglandin analogues require control of multiple stereocenters — including the stereochemistry of the cyclopentyl ring system and aliphatic chain — in molecules that cost $1M+ per kilogram due to the extreme chemical synthesis challenge. Chirogate's expertise in asymmetric synthesis for prostaglandins demonstrates that small Taiwanese specialty chemistry companies can hold critical supply chain positions in global pharmaceutical markets — ophthalmic surgeons worldwide depend on APIs from a company most of their patients have never heard of.
Gland Pharma Limited(GLAND)
HQ IN8% share
Indian sterile injectables CDMO; majority owned by Fosun Pharma (China); received FDA ANDA approval for generic latanoprost ophthalmic solution December 2024.